- Conditions
- Pelvic Organ Prolapse (POP), Stress Urinary Incontinence (SUI), Postoperative Pain
- Interventions
- Suzetrigine, Opioid Analgesics (Tramadol or Oxycodone), Scheduled Acetaminophen and Ibuprofen
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 70
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pelvic Organ Prolapse, Post Operative Pain
- Interventions
- Quadratus Lumborum (QL) Block, Enhanced Recovery After Surgical (ERAS) Protocol
- Procedure
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia
- Interventions
- eltrombopag olamine
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- HIV Testing
- Interventions
- Intervention, Enhanced Standard of Care, Traditional Standard of Care
- Behavioral
- Lead sponsor
- City University of New York, School of Public Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,458 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Crohn Disease
- Interventions
- Radiotracer Injection, Contrast Media, Magnetic Resonance, Blood Draw, Glucagon, Imaging, Oral contrast media application
- Drug · Diagnostic Test
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Gynecologic Surgical Procedures, Gastric Injury, Aspiration, Nausea, Postoperative, Postoperative Complications, Enhanced Recovery After Surgery, Laparoscopy
- Interventions
- Gastric decompression (oropharyngeal or nasopharyngeal gastric tube)
- Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Atrial Fibrillation, Stroke
- Interventions
- Oral anticoagulant
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Dental Caries
- Interventions
- Chlorhexidine mouth rinse, Xylitol chewing gum
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- Female only
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Gingivitis, DMFT Index, Dental Plaque Index, Oral Hygiene Education Methods, Oral Hygiene Reinforcement During Fixed Orthodontic Treatment, Motivational Interview, OHI
- Interventions
- Motivational Interviewing-Based Counseling, Standard Oral Health Education
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 14 Years to 19 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Cleft Lip and Cleft Palate, Cleft Lip Palate, Cleft Lip and/or Palate, Cleft Palate, Cleft Palate Children, Cleft Palates, Cleft Palate Repair
- Interventions
- Early intervention for language, articulation and palatal function skills
- Behavioral
- Lead sponsor
- Old Dominion University
- Other
- Eligibility
- 6 Months to 12 Months
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Patient Noncompliance
- Interventions
- haloperidol decanoate, haloperidol, Customized Adherence Enhancement
- Drug · Behavioral
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
- Interventions
- Smoking Prevention Usual Care, Counseling Intervention
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Urinary Retention
- Interventions
- Tamsulosin, Placebo
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 21 Years to 99 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- HIV, PrEP, PrEP Adherence
- Interventions
- LYPS, Enhanced Standard of Care
- Other
- Lead sponsor
- Westat
- Other
- Eligibility
- 13 Years to 24 Years
- Enrollment
- 272 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 1 more
- Conditions
- Focus is on Healthy Subjects
- Interventions
- Reusable, Transparent, and Reconfigurable N95-Equivalent Respirator Masks: Design, Fabrication, and Clinical Trials for Enhanced Adoption
- Device
- Lead sponsor
- SEEUS95 Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 28
- States / cities
- Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
- Conditions
- Leukemia, Myeloma, Myeloproliferative Diseases
- Interventions
- Fludarabine, Melphalan, Alemtuzumab, Stem Cell infusion, Tacrolimus, Mini Methotrexate, G-CSF, Donor Lymphocyte Infusion (DLI), AP1903, Methylprednisolone, Questionnaire
- Drug · Procedure · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Head and Neck Cancer, Carcinoma, Squamous Cell, Head and Neck Cancers
- Interventions
- Lapatinib, Radiotherapy (radiation), G.E. Healthcare 1.5T MR, systems revision 12.0 M5, DCE-MRI
- Drug · Procedure · Device
- Lead sponsor
- Quynh-Thu Le
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 5
- States / cities
- Stanford, California • Gainsville, Florida • New York, New York + 2 more
- Conditions
- Food Allergy
- Interventions
- Education and Opportunities on Early Introduction, Clinician Supervised Feeding of Known Allergenic Food
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 4 Months to 11 Months
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Pneumonia, Lower Respiratory Tract Infection
- Interventions
- Enhanced Oral Care, Usual oral care
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 834 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Asthma in Children
- Interventions
- Multicomponent program
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Mucinous Adenocarcinoma, Recurrent Fallopian Tube Transitional Cell Carcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Seromucinous Carcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Transitional Cell Carcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma, Refractory Fallopian Tube Clear Cell Adenocarcinoma, Refractory Fallopian Tube Endometrioid Adenocarcinoma, Refractory Fallopian Tube High Grade Serous Adenocarcinoma, Refractory Fallopian Tube Mucinous Adenocarcinoma, Refractory Fallopian Tube Transitional Cell Carcinoma, Refractory Fallopian Tube Undifferentiated Carcinoma, Refractory Low Grade Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian Endometrioid Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma, Refractory Ovarian Low Grade Serous Adenocarcinoma, Refractory Ovarian Mucinous Adenocarcinoma, Refractory Ovarian Seromucinous Carcinoma, Refractory Ovarian Transitional Cell Carcinoma, Refractory Ovarian Undifferentiated Carcinoma, Refractory Primary Peritoneal Clear Cell Adenocarcinoma, Refractory Primary Peritoneal Endometrioid Adenocarcinoma, Refractory Primary Peritoneal High Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Transitional Cell Carcinoma, Refractory Primary Peritoneal Undifferentiated Carcinoma
- Interventions
- Biospecimen Collection, Cediranib Maleate, Computed Tomography, Computed Tomography with Contrast, Durvalumab, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 384
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 288 more
- Conditions
- Early Childhood Dental Caries
- Interventions
- Motivational interviewing, Enhanced community services
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 15 Years to 44 Years
- Enrollment
- 1,134 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Critically Ill
- Interventions
- PEP uP Protocol, Metoclopramide
- Other · Drug
- Lead sponsor
- Clinical Evaluation Research Unit at Kingston General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Jamaica, New York • Roanoke, Virginia